Tenocyclidine
Tenocyclidine[edit]
Tenocyclidine (TCP) is a dissociative anesthetic drug that was developed in the 1950s. It is chemically related to phencyclidine (PCP) and ketamine, and it acts primarily as an NMDA receptor antagonist.
Chemical structure and properties[edit]
Tenocyclidine is a member of the arylcyclohexylamine class of compounds. Its chemical structure consists of a cyclohexane ring bound to a piperidine ring and a phenyl group. The molecular formula of Tenocyclidine is C16H23N.
Pharmacology[edit]
Tenocyclidine acts as a non-competitive antagonist of the NMDA receptor, which is a subtype of glutamate receptor. By blocking the NMDA receptor, Tenocyclidine disrupts the normal excitatory neurotransmission in the brain, leading to its anesthetic and dissociative effects.
Effects[edit]
The effects of Tenocyclidine are similar to those of other dissociative anesthetics such as PCP and ketamine. These effects include:
- Dissociation from the environment
- Analgesia
- Hallucinations
- Euphoria
- Altered perception of time and space
History[edit]
Tenocyclidine was first synthesized in the 1950s as part of research into new anesthetic agents. However, due to its potent psychoactive effects and potential for abuse, it was never marketed for medical use. It has been used in scientific research to study the effects of NMDA receptor antagonism.
Legal status[edit]
Due to its potential for abuse and lack of medical use, Tenocyclidine is classified as a controlled substance in many countries. It is listed as a Schedule I substance under the Controlled Substances Act in the United States, indicating that it is considered to have a high potential for abuse and no accepted medical use.
